Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$485.42 USD

485.42
904,979

+3.15 (0.65%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Exact Sciences (EXAS) Cologuard Sales Up but Costs Rise

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Boston Scientific (BSX) Hurt by Price and Volume Issues

by Zacks Equity Research

The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.

DexCom (DXCM) to Boost Diabetes Management With New Approval

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.

Here's Why You Should Add Phibro (PAHC) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and diverse product lines.

Here's Why You Should Hold on to Medtronic (MDT) Stock For Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.

McKesson (MCK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, McKesson (MCK) closed at $284.85, marking a +1.29% move from the previous day.

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Here's Why You Should Hold NextGen (NXGN) Stock For Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.

Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario

by Zacks Equity Research

Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.

Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza

by Zacks Equity Research

Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.

Here's Why You Should Retain Illumina (ILMN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Illumina's (ILMN) better-than-expected results and strategic collaborations.

Here's Why You Should Hold Onto Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.

Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes

by Zacks Equity Research

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays

by Zacks Equity Research

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Cardiovascular Systems (CSII) Finances New DCB Development

by Zacks Equity Research

Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Medtronic (MDT) Inks Deal to Offer Touch Surgery Enterprise

by Zacks Equity Research

Medtronic's (MDT) Touch Surgery Enterprise gives surgical teams a powerful new tool to enhance patient care by simplifying the process to capture and analyze surgical videos.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Accuray's (ARAY) CyberKnife S7 System Gets Chosen by CARTI

by Zacks Equity Research

Accuray's (ARAY) CyberKnife S7 System gets selected by the CARTI medical care team, thereby offering better cancer care in Arkansas via expanded access to advanced technology.

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.

Allscripts (MDRX) Up 4.5% Since Q4 Earnings: What's Driving It?

by Zacks Equity Research

Allscripts' (MDRX) stock rallies on better-than-expected fourth-quarter performance and recent alliances.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

McKesson (MCK) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.